vs
Side-by-side financial comparison of Cardio Diagnostics Holdings, Inc. (CDIO) and Celldex Therapeutics, Inc. (CLDX). Click either name above to swap in a different company.
Celldex Therapeutics, Inc. is the larger business by last-quarter revenue ($120.0K vs $3.6K, roughly 33.8× Cardio Diagnostics Holdings, Inc.). On growth, Cardio Diagnostics Holdings, Inc. posted the faster year-over-year revenue change (-21.2% vs -89.8%). Cardio Diagnostics Holdings, Inc. produced more free cash flow last quarter ($-5.9M vs $-65.2M). Over the past eight quarters, Celldex Therapeutics, Inc.'s revenue compounded faster (-12.3% CAGR vs -52.8%).
Cardio Diagnostics Holdings, Inc. is a precision cardiovascular healthcare company that develops and commercializes integrated genetic and epigenetic diagnostic tests for early detection of coronary heart disease, heart failure, and other cardiovascular conditions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, focusing on delivering accessible, personalized cardiovascular care solutions.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
CDIO vs CLDX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $3.6K | $120.0K |
| Net Profit | — | $-81.3M |
| Gross Margin | — | — |
| Operating Margin | — | -72628.3% |
| Net Margin | — | -67764.2% |
| Revenue YoY | -21.2% | -89.8% |
| Net Profit YoY | 3.6% | -72.7% |
| EPS (diluted) | — | $-1.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.6K | $120.0K | ||
| Q3 25 | $2.9K | $0 | ||
| Q2 25 | $7.5K | $730.0K | ||
| Q1 25 | $940 | $695.0K | ||
| Q4 24 | $4.5K | $1.2M | ||
| Q3 24 | $6.6K | $3.2M | ||
| Q2 24 | $7.9K | $2.5M | ||
| Q1 24 | $15.9K | $156.0K |
| Q4 25 | — | $-81.3M | ||
| Q3 25 | $-1.7M | $-67.0M | ||
| Q2 25 | $-1.7M | $-56.6M | ||
| Q1 25 | $-1.6M | $-53.8M | ||
| Q4 24 | — | $-47.1M | ||
| Q3 24 | $-1.4M | $-42.1M | ||
| Q2 24 | $-1.3M | $-35.8M | ||
| Q1 24 | $-4.2M | $-32.8M |
| Q4 25 | — | -72628.3% | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | -8747.5% | ||
| Q1 25 | -173463.8% | -9027.2% | ||
| Q4 24 | — | -4768.3% | ||
| Q3 24 | -21412.9% | -1633.5% | ||
| Q2 24 | -16295.6% | -1854.2% | ||
| Q1 24 | -26105.3% | -26030.8% |
| Q4 25 | — | -67764.2% | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | -7753.4% | ||
| Q1 25 | -173943.0% | -7740.4% | ||
| Q4 24 | — | -4007.8% | ||
| Q3 24 | -21467.6% | -1320.0% | ||
| Q2 24 | -16365.9% | -1434.8% | ||
| Q1 24 | -26140.0% | -21030.8% |
| Q4 25 | — | $-1.23 | ||
| Q3 25 | $-0.98 | $-1.01 | ||
| Q2 25 | $-0.97 | $-0.85 | ||
| Q1 25 | $-0.97 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-1.73 | $-0.64 | ||
| Q2 24 | $-1.71 | $-0.54 | ||
| Q1 24 | $-5.93 | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $518.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.0M | $527.2M |
| Total Assets | $7.8M | $583.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $518.6M | ||
| Q3 25 | — | $583.2M | ||
| Q2 25 | — | $630.3M | ||
| Q1 25 | — | $673.3M | ||
| Q4 24 | — | $725.3M | ||
| Q3 24 | — | $756.0M | ||
| Q2 24 | — | $802.3M | ||
| Q1 24 | — | $823.8M |
| Q4 25 | $7.0M | $527.2M | ||
| Q3 25 | $8.2M | $598.4M | ||
| Q2 25 | $9.7M | $655.4M | ||
| Q1 25 | $11.4M | $703.0M | ||
| Q4 24 | $9.6M | $747.0M | ||
| Q3 24 | $3.7M | $785.9M | ||
| Q2 24 | $3.1M | $813.7M | ||
| Q1 24 | $3.0M | $838.6M |
| Q4 25 | $7.8M | $583.0M | ||
| Q3 25 | $8.8M | $648.4M | ||
| Q2 25 | $10.4M | $692.4M | ||
| Q1 25 | $12.3M | $739.5M | ||
| Q4 24 | $10.6M | $792.3M | ||
| Q3 24 | $4.5M | $823.2M | ||
| Q2 24 | $4.0M | $845.6M | ||
| Q1 24 | $4.3M | $868.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.7M | $-63.9M |
| Free Cash FlowOCF − Capex | $-5.9M | $-65.2M |
| FCF MarginFCF / Revenue | -166361.5% | -54350.8% |
| Capex IntensityCapex / Revenue | 5269.1% | 1067.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.5M | $-213.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.7M | $-63.9M | ||
| Q3 25 | $-1.4M | $-48.6M | ||
| Q2 25 | $-1.6M | $-44.0M | ||
| Q1 25 | $-1.4M | $-54.4M | ||
| Q4 24 | $-5.0M | $-32.5M | ||
| Q3 24 | $-1.2M | $-55.3M | ||
| Q2 24 | $-1.2M | $-29.3M | ||
| Q1 24 | $-1.2M | $-40.6M |
| Q4 25 | $-5.9M | $-65.2M | ||
| Q3 25 | $-1.6M | $-49.1M | ||
| Q2 25 | $-1.6M | $-44.7M | ||
| Q1 25 | $-1.4M | $-54.6M | ||
| Q4 24 | $-5.2M | $-33.2M | ||
| Q3 24 | $-1.2M | $-55.9M | ||
| Q2 24 | $-1.4M | $-29.6M | ||
| Q1 24 | $-1.3M | $-41.0M |
| Q4 25 | -166361.5% | -54350.8% | ||
| Q3 25 | -54509.7% | — | ||
| Q2 25 | -21273.1% | -6127.8% | ||
| Q1 25 | -149562.6% | -7861.4% | ||
| Q4 24 | -115422.6% | -2828.3% | ||
| Q3 24 | -17942.3% | -1751.2% | ||
| Q2 24 | -17513.3% | -1185.0% | ||
| Q1 24 | -7866.9% | -26270.5% |
| Q4 25 | 5269.1% | 1067.5% | ||
| Q3 25 | 5703.5% | — | ||
| Q2 25 | 250.1% | 99.7% | ||
| Q1 25 | 615.6% | 38.1% | ||
| Q4 24 | 4759.9% | 64.3% | ||
| Q3 24 | 353.3% | 17.1% | ||
| Q2 24 | 2133.4% | 11.0% | ||
| Q1 24 | 125.5% | 220.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
